105P Discovery of bioactive small molecule inhibitors of human PD1-PDL1 interaction

ConclusionIn summary, we have been successful in identifying novel, non-peptide small molecule inhibitors of PD1-PDL1 interaction through rational design. Considering their remarkable activity and clinical status, they may present immediate clinical potential against cancers expressing PDL1. They may also prove to be ideal starting points for the design of more potent, selective drug-like inhibitors of PD1-PDL1 interaction.Legal entity responsible for the studyWidener University, Chester, PA, USA.FundingW. W. Smith Charitable Trust.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research